Celerion
Celerion Employees
8 people indexed:
-
Abby Ferraro
Executive Vice President and General Counsel
x0uu.1hqwpg7@g14uzk7s.tvg Sign up to see email87q1.972q5t7@z1u6wg84.50s Sign up to see email -
Chad Briscoe
Executive Vice President, Global Bioanalytical Sciences
t3t0.wfg5uu0@xkgjx861.86q Sign up to see emailx0qu.2j6xyqz@tf0fk9vp.6jj Sign up to see email -
David Maya
Executive Vice President, Global Business Development
kzh2w.h7zh@qkxzwhpk.gfu Sign up to see emailbqgux.fu63@w67wbxt3.hf2 Sign up to see email -
J. Fred Pritchard
Vice President, Global Drug Development
8.v057.187x5qzg8@y7u9xw4z.w3v Sign up to see email9.286w.s59w94239@0wkgx77k.gzw Sign up to see email -
JoAnne Rosal
Chief Financial and Administrative Officer
vv1khv.wq92g@5b2k8dfv.6db Sign up to see email7uxvvx.zyq73@66xt2b0y.k1v Sign up to see email -
Michelle Combs
Executive Vice President, Data Management and Biometrics
v3ww238f.yqu1g@0g0j0473.q9w Sign up to see emailk759fq5a.p2g36@wvp07qjj.wak Sign up to see email -
Philip Bach
Executive Vice President, Global Clinical Research
dj4uw2.4vwt@10s66y4q.wv1 Sign up to see email0g6z76.0572@qdg9v14j.k2d Sign up to see email -
fyqg4.4zkx73wg@82z1bgy3.p7p Sign up to see email
Celerion's Commitment to Diversity, Equity, Inclusion, and Belonging
Celerion is deeply committed to fostering a workplace culture grounded in diversity, equity, inclusion, and belonging (DEIB). The company recognizes that a diverse and inclusive workforce drives innovation and enhances employee engagement. By promoting equitable opportunities and creating an environment where all employees feel valued and included, Celerion aims to reflect the diverse communities it serves. This commitment is evidenced by various initiatives and policies designed to support DEIB at all organizational levels. These efforts not only enhance team dynamics and productivity but also ensure that Celerion remains a competitive and forward-thinking leader in the clinical research industry.
Celerion's Privacy and Data Security Program
Celerion maintains a robust privacy and data security program that adheres to global regulatory standards. This program is crucial in ensuring the protection of sensitive data, including patient information and proprietary research data. By complying with regulations such as GDPR in Europe and HIPAA in the United States, Celerion demonstrates its dedication to safeguarding data integrity and confidentiality. The company employs advanced security measures and best practices to mitigate risks and prevent data breaches. This steadfast commitment to data security not only builds trust with clients and stakeholders but also supports the integrity of Celerion's research outcomes.
Celerion's Comprehensive Drug Development Services
Celerion offers an extensive suite of services for Phases 1-3 of drug development, providing a seamless transition from early-stage clinical trials to later phases. These services include clinical pharmacology, patient studies, and clinical trial management, ensuring comprehensive support throughout the drug development lifecycle. Celerion's expertise in executing complex clinical trials enables pharmaceutical and biotechnology companies to bring new therapies to market efficiently and safely. By leveraging state-of-the-art technologies and methodologies, Celerion ensures data accuracy and reliability, ultimately contributing to the advancement of medical science and patient care.
Celerion's Bioanalytical Sciences Services
Celerion provides a wide array of bioanalytical sciences services, including pharmacokinetics/pharmacodynamics (PK/PD), immunogenicity, biomarkers, biosimilars, gene therapy, and metabolite profiling. These services are critical in understanding the pharmacological and toxicological properties of new drugs. Celerion's advanced bioanalytical capabilities support the development of innovative therapies by providing precise and reliable data. The company's expertise in areas such as biomarkers and gene therapy is particularly valuable for the development of personalized medicine and cutting-edge treatments. By offering comprehensive bioanalytical services, Celerion helps its clients make informed decisions and accelerate the drug development process.
Celerion's Global Operations
Celerion operates on a global scale with facilities across North America, Europe, and Asia, enabling it to manage clinical trials and research projects worldwide. This extensive geographical presence allows Celerion to access diverse patient populations and adhere to regional regulatory requirements. The company's global infrastructure supports seamless coordination and execution of multi-national clinical trials, enhancing the efficiency and reach of its services. By maintaining a strong international footprint, Celerion can provide its clients with the flexibility and logistical support needed to successfully conduct global clinical research initiatives.
Celerion's Environmental Sustainability Initiatives
Celerion is committed to environmental sustainability and actively implements initiatives to minimize its carbon footprint and waste. These efforts include energy-efficient practices, waste reduction programs, and sustainable resource management. By prioritizing environmental stewardship, Celerion aims to reduce its impact on the planet while maintaining high standards of operational efficiency. The company's sustainability initiatives not only align with global environmental goals but also reflect its dedication to corporate social responsibility. Through continuous improvement and innovation in sustainability practices, Celerion strives to contribute positively to environmental conservation and sustainable development.